JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 25, 2005; DOI: 10.1124/jpet.104.081893


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.081893v1
313/3/1217    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Robert P. Hanzlik
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanzlik, R. P.
Right arrow Articles by Fisher, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanzlik, R. P.
Right arrow Articles by Fisher, D. H.


Received for publication December 28, 2004.
Revised February 13, 2005.
Accepted for publication February 18, 2005.

Relative Bioavailability of Calcium from Calcium Formate, Calcium Citrate and Calcium Carbonate

Robert P. Hanzlik 1*, Stephen C. Fowler 1, Daniel H. Fisher 2

1 University of Kansas 2 AAI Development

* Address correspondence to: E-mail: rhanzlik{at}ku.edu

Abstract

Calcium is an essential nutrient required in substantial amounts but many diets are deficient in calcium making supplementation necessary or desirable. The objective of this study was to compare the oral bioavailability of calcium from calcium formate, a new experimental dietary calcium supplement, to that of calcium citrate and calcium carbonate. In a four-way crossover study either a placebo or 1200 mg calcium as calcium carbonate, calcium citrate or calcium formate were administered orally to 14 healthy adult female volunteers who had fasted overnight. After calcium carbonate the maximum rise in serum calcium (ca. 4%), and the fall in serum iPTH (ca. 20-40%), did not differ significantly from placebo. After calcium citrate the changes were modestly but significantly (p <0.05) greater, but only at times 135-270 min after ingestion. In contast, within 60 min after calcium formate serum calcium rose by ca. 15% and serum iPTH fell by 70%. The mean increment in AUC (0-270 min) for serum calcium after calcium formate (378 mg·min/dL) was double that for calcium citrate (178 mg·min/dL; p < 0.01), while the latter was only modestly greater than either placebo (107; p < 0.05) or calcium carbonate (91; p < 0.05). In this study calcium formate was clearly superior to both calcium carbonate and calcium citrate in ability to deliver calcium to the bloodstream after oral administration. Calcium formate may thus offer significant advantages as a dietary calcium supplement.


Key words: calcium absorption, calcium bioavailability, calcium carbonate, calcium citrate, calcium formate, parathyroid hormone





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.